Digital fluoroscopy to quantify lung tumor motion: Potential for patient-specific planning target volumes

被引:62
作者
Sixel, KE
Ruschin, M
Tirona, R
Cheung, PCF
机构
[1] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada
[2] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada
[3] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2003年 / 57卷 / 03期
关键词
lung cancer; digital fluoroscopy; tumor motion; PTV;
D O I
10.1016/S0360-3016(03)00713-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To apply digital fluoroscopy integrated with CT simulation to measure lung tumor motion and aid in the quantification of individualized planning target volumes. Methods and Materials: A flat panel digital fluoroscopy unit was modified and integrated with a CT simulator. The stored fluoroscopy images were overlaid with digitally reconstructed radiographs, allowing measurement of the observed lung tumor motion in relation to the corresponding contours on the static digitally reconstructed radiographs. CT simulation and digital fluoroscopy was performed on 10 patients with non-small-cell lung cancer. Actual tumor motion was measured in three dimensions using the overlaid images. Results: Combining the dynamic data with digitally reconstructed radiographs allowed the tumor shadow from the fluoroscopy to be tracked in relation to the CT lung tumor contour. For all patients, the extent of tumor motion in three dimensions was unique. The motion was greatest in the superoinferior direction and minimal in the AP and lateral directions. Conclusion: We have developed a tool that allows CT simulation to be combined with digital fluoroscopy. Quantitative evaluation of the tumor motion in relation to the CT plan allows for customization of the planning target volume. The variability observed clearly demonstrates the need to generate patient-specific internal motion margins. (C) 2003 Elsevier Inc.
引用
收藏
页码:717 / 723
页数:7
相关论文
共 27 条
[1]   Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer [J].
Armstrong, J ;
Raben, A ;
Zelefsky, M ;
Burt, M ;
Leibel, S ;
Burman, C ;
Kutcher, G ;
Harrison, L ;
Hahn, C ;
Ginsberg, R ;
Rusch, V ;
Kris, M ;
Fuks, Z .
RADIOTHERAPY AND ONCOLOGY, 1997, 44 (01) :17-22
[2]   A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable nonsmall cell lung cancer: final report of an Australian multi-centre trial [J].
Ball, D ;
Bishop, J ;
Smith, J ;
O'Brien, P ;
Davis, S ;
Ryan, G ;
Olver, I ;
Toner, G ;
Walker, Q ;
Joseph, D .
RADIOTHERAPY AND ONCOLOGY, 1999, 52 (02) :129-136
[3]   Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results [J].
Breathnach, OS ;
Freidlin, B ;
Conley, B ;
Green, MR ;
Johnson, DH ;
Gandara, DR ;
O'Connell, M ;
Shepherd, FA ;
Johnson, BE .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1734-1742
[4]   Fluoroscopic study of tumor motion due to breathing: Facilitating precise radiation therapy for lung cancer patients [J].
Chen, QS ;
Weinhous, MS ;
Deibel, FC ;
Ciezki, JP ;
Macklis, RM .
MEDICAL PHYSICS, 2001, 28 (09) :1850-1856
[5]   Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial [J].
Dillman, RO ;
Herndon, J ;
Seagren, SL ;
Eaton, WL ;
Green, MR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (17) :1210-1215
[6]  
Eberhardt W, 2000, ANN ONCOL, V11, P85
[7]   3-DIMENSIONAL CONFORMAL RADIOTHERAPY IN BRONCHOGENIC-CARCINOMA - CONSIDERATIONS FOR IMPLEMENTATION [J].
EMAMI, B ;
GRAHAM, MV ;
PURDY, JA .
LUNG CANCER, 1994, 11 :S117-S128
[8]   Relating radiation-induced regional lung injury to changes in pulmonary function tests [J].
Fan, M ;
Marks, LB ;
Lind, P ;
Hollis, D ;
Woel, RT ;
Bentel, GG ;
Anscher, MS ;
Shafman, TD ;
Coleman, RE ;
Jaszczak, RJ ;
Munley, MT .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (02) :311-317
[9]  
FORD E, 2002, MED PHYS, V29, P1189
[10]   Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer [J].
Furuse, K ;
Fukuoka, M ;
Kawahara, M ;
Nishikawa, H ;
Takada, Y ;
Kudoh, S ;
Katagami, N ;
Ariyoshi, Y .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2692-2699